101.46 ¥/$ (5 p.m.)

Sorry, but your browser needs Javascript to use this site. LONDON – GlaxoSmithKline faces new allegations of corruption, this time in Syria, where the drugmaker and its distributor have been accused of paying bribes to secure business, according to a whistleblower’s email reviewed by Reuters.